NVision is a quantum biotech startup based in Ulm, Germany, with Tier 1 investors from the USA and Europe. We are just leaving stealth mode, moving from local R&D to global commercialization and expansion.

We are developing a technology that will enable MRI-based imaging of real-time metabolism in the body, with tremendous potential for research and applications in oncology, cardiology, neurology and more. Our company brings together expertise in physics, chemistry, engineering and medicine, and we are collaborating with scientists and clinicians from top medical and research centers such as Memorial Sloan Kettering in New York, MD Anderson in Texas, Technical University of Munich, Cambridge University in the UK and more.

NVision is developing fast, robust and easy-to-use hyperpolarization technology for preclinical and clinical research in our Polaris product line. Those devices are placed close to an MRI scanner in a clinical environment or a research lab to produce hyperpolarized contrast agents on demand. The hyperpolarized solution is prepared in a fast, fully-automated, multi-step process including chemical reactions, polarization transfer and several purification steps. We develop our commercial products in close collaboration with a product development partner, while the process development as well as the design of test setups and prototypes is done in-house. 

We offer a dynamic international working environment, with immense room for growth, that encourages personal initiative and open communication.